Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.76 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ATM | Q13315 | 2/20 | 0.73 |
| ▸ | PGR | P06401 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL13753350 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL14031683 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8173336 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL6353316 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL2348477 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL4252 | 1.00 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL679202 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7621246 | 0.99 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4473131-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | OncoAssure Limited (IE) | 2024-12-11 | — | — | EP | claimed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023186985-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | ONCOASSURE LIMITED (IE) | 2023-10-05 | — | — | WO | claimed |
| EP-4253567-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | OncoAssure Limited (IE) | 2023-10-04 | — | — | EP | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| WO-2023104380-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-15 | — | — | WO | claimed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| EP-3250213-B1 | COMPOSITIONS CONTAINING ARSENIC FOR USE IN METHODS OF TREATMENT | EUPHARMA PTY LTD (AU) | 2023-06-07 | — | — | EP | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| WO-2025104045-A1 | ALECTINIB FOR THE TREATMENT OF ALK FUSION-POSITIVE SOLID OR CNS TUMOURS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| WO-2025045901-A1 | TREATMENT OF NON SMALL CELL LUNG CANCER WITH ALECTINIB | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| EP-4473131-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | OncoAssure Limited (IE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | disclosed |
| CN-112538038-B | 2-indolone ERR alpha inverse agonist and pharmaceutical composition and application thereof | 暨南大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-109836427-B | Pyrimidopyrimidinone compounds and application thereof | 暨南大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114072387-A | Indazole compound and medicinal composition and application thereof | 暨南大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-113966331-A | Triaromatic ring compound containing urea structure and application thereof | 暨南大学 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | RECQL 553/4885BLM 1285/4885ESR1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.